TVRD•benzinga•
Tvardi Therapeutics Completes Enrollment For Lead Program In Phase 2 Clinical Trial Of TTI-101 For Patients With Idiopathic Pulmonary Fibrosis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 27, 2025 by benzinga